In a Phase 2 study examining the efficacy of mocetinostat, an oral HDACi, researchers investigated its effects on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have mutations in the CREBBP/EP300 genes. The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.